ArticleClinical epigenetics2025
Restoring endogenous Dlg4/PSD95 expression by an artificial transcription factor ameliorates cognitive and motor learning deficits in the R6/2 mouse model of Huntington's disease.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHuntington's disease (HD) is an incurable hereditary disorder caused by an expansion of CAG repeats in exon 1 of the Huntingtin gene (HTT). HD is characterized by motor dysfunction and cognitive decline. The pathophysiology of HD begins in cortico-striatal circuits and later spreads to other brain regions, notably the hippocampus. At the cellular level, structural changes in synapses have been observed prior to neuronal degeneration, significantly disrupting the formation and maintenance of neuronal circuits. The postsynaptic density protein 95 (PSD-95, hereafter Dlg4/PSD95) is a key synaptic plasticity protein reduced in HD and other neurodegenerative diseases such as Alzheimer's disease (AD). Epigenetic silencing of plasticity and memory genes contributes to AD pathology and cognitive impairment. To restore endogenous Dlg4/PSD95 expression in AD, we previously developed an epigenetic editing strategy where a zinc finger DNA-binding domain targeting the Dlg4/PSD95 gene promoter was fused to the transactivation domain VP64 and driven under a CMV promoter. AAV-PhP.B-mediated delivery of this artificial transcription factor (ATF) CMV-PSD95-6ZF-VP64 improved cognition in an AD mouse model. Here, we assessed the therapeutic potential of AAV9-mediated delivery of the synapsin-driven ATF PSD95-6ZF-VP64 in the R6/2 HD mouse model.
resultsConsistent with the previous studies, R6/2 mice exhibited reduced hippocampal Dlg4/PSD95 mRNA and protein levels in young adulthood (7 weeks), which persisted into early adulthood (14 weeks). Starting at adolescents (4 weeks), the R6/2 mice also displayed motor (i.e., accelerated rotarod) and cognitive (i.e., Barnes maze and object location memory) impairments. In wild-type primary hippocampal cultures, AAV9-PSD95-6ZF-VP64 led to an increase in synaptic PSD-95 clusters and spine size. Intracerebroventricular injections of neonatal R6/2 mice with AAV9-PSD95-6ZF-VP64 elevated hippocampal Dlg4/PSD95 expression levels to those observed in control non-transgenic mice. Importantly, AAV9-PSD95-6ZF-VP64 effectively improved hippocampal-dependent deficits in spatial learning and memory in young adult HD mice, as well as impairments in motor coordination and motor skill learning, with these benefits persisting into adulthood.
conclusionThis work validates Dlg4/PSD95 as a key player in the prodromal phase of HD pathology and establishes the ATF PSD95-6ZF-VP64 as an attractive therapeutic tool for treating the disease's early phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.